Entacom Plus 100 Tablet contains a combination of Levodopa (100mg), Carbidopa (25mg), and Entacapone (200mg), formulated to manage symptoms of Parkinson’s disease. Levodopa serves as a precursor to dopamine, replenishing diminished dopamine levels in the brain, thereby improving motor function. Carbidopa inhibits peripheral decarboxylation of Levodopa, enhancing its central availability and reducing peripheral side effects such as nausea. Entacapone, a selective and reversible catechol-O-methyltransferase (COMT) inhibitor, prolongs the half-life of Levodopa by preventing its peripheral metabolism, resulting in more stable and sustained dopaminergic stimulation. This combination is indicated for patients experiencing motor fluctuations and wearing-off phenomena associated with Parkinson’s disease, providing improved symptom control and quality of life. Entacom Plus 100 is typically administered orally, with dosage individualized based on clinical response and tolerability. Common adverse effects may include dyskinesia, nausea, orthostatic hypotension, and gastrointestinal disturbances. Caution is advised in patients with a history of cardiac, hepatic, or psychiatric disorders. Regular monitoring by a healthcare professional is recommended to optimize therapeutic outcomes and minimize potential side effects. This combination therapy represents an effective approach to managing advanced Parkinson’s disease symptoms by enhancing and prolonging dopaminergic activity in the central nervous system.